
Stephen L. Rawlings
Examiner (ID: 18470, Phone: (571)272-0836 , Office: P/1643 )
| Most Active Art Unit | 1643 |
| Art Unit(s) | 1642, 1643, 1646 |
| Total Applications | 1483 |
| Issued Applications | 633 |
| Pending Applications | 153 |
| Abandoned Applications | 701 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10573098
[patent_doc_number] => 09295720
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-03-29
[patent_title] => 'Immunotherapeutic method for treating prostate cancer'
[patent_app_type] => utility
[patent_app_number] => 13/819622
[patent_app_country] => US
[patent_app_date] => 2011-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 18
[patent_no_of_words] => 11147
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 169
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13819622
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/819622 | Immunotherapeutic method for treating prostate cancer | Aug 28, 2011 | Issued |
Array
(
[id] => 7756537
[patent_doc_number] => 20120028829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-02
[patent_title] => 'ANTI-HEDGEHOG ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 13/217191
[patent_app_country] => US
[patent_app_date] => 2011-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 30869
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0028/20120028829.pdf
[firstpage_image] =>[orig_patent_app_number] => 13217191
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/217191 | ANTI-HEDGEHOG ANTIBODIES | Aug 23, 2011 | Abandoned |
Array
(
[id] => 7790959
[patent_doc_number] => 20120052515
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-03-01
[patent_title] => 'THERAPEUTIC APPLICATIONS OF NONCOVALENT DIMERIZING ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 13/215903
[patent_app_country] => US
[patent_app_date] => 2011-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6117
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0052/20120052515.pdf
[firstpage_image] =>[orig_patent_app_number] => 13215903
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/215903 | THERAPEUTIC APPLICATIONS OF NONCOVALENT DIMERIZING ANTIBODIES | Aug 22, 2011 | Abandoned |
Array
(
[id] => 7790512
[patent_doc_number] => 20120052068
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-03-01
[patent_title] => 'AUTOPHILIC ANTIBODIES AND METHOD OF MAKING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 13/215928
[patent_app_country] => US
[patent_app_date] => 2011-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 12126
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0052/20120052068.pdf
[firstpage_image] =>[orig_patent_app_number] => 13215928
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/215928 | AUTOPHILIC ANTIBODIES AND METHOD OF MAKING THE SAME | Aug 22, 2011 | Abandoned |
Array
(
[id] => 7766151
[patent_doc_number] => 20120034215
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-09
[patent_title] => 'ANTI-MST1R ANTIBODIES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/206736
[patent_app_country] => US
[patent_app_date] => 2011-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 37
[patent_no_of_words] => 14929
[patent_no_of_claims] => 61
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0034/20120034215.pdf
[firstpage_image] =>[orig_patent_app_number] => 13206736
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/206736 | Anti-MST1R antibodies and uses thereof | Aug 9, 2011 | Issued |
Array
(
[id] => 7580265
[patent_doc_number] => 20110294148
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-01
[patent_title] => 'TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER'
[patent_app_type] => utility
[patent_app_number] => 13/198519
[patent_app_country] => US
[patent_app_date] => 2011-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 20698
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0294/20110294148.pdf
[firstpage_image] =>[orig_patent_app_number] => 13198519
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/198519 | TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER | Aug 3, 2011 | Abandoned |
Array
(
[id] => 7650888
[patent_doc_number] => 20110300157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-08
[patent_title] => 'METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 13/195710
[patent_app_country] => US
[patent_app_date] => 2011-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 84773
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0300/20110300157.pdf
[firstpage_image] =>[orig_patent_app_number] => 13195710
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/195710 | METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS | Jul 31, 2011 | Abandoned |
Array
(
[id] => 8293968
[patent_doc_number] => 08221749
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-07-17
[patent_title] => 'Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/194854
[patent_app_country] => US
[patent_app_date] => 2011-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 41795
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13194854
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/194854 | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof | Jul 28, 2011 | Issued |
Array
(
[id] => 7560855
[patent_doc_number] => 20110274687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-11-10
[patent_title] => 'METHODS OF TREATING TSLP-RELATED INFLAMMATORY DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 13/185021
[patent_app_country] => US
[patent_app_date] => 2011-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 33200
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0274/20110274687.pdf
[firstpage_image] =>[orig_patent_app_number] => 13185021
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/185021 | Methods of treating TSLP-related inflammatory disorders | Jul 17, 2011 | Issued |
Array
(
[id] => 7731527
[patent_doc_number] => 20120014947
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-19
[patent_title] => 'METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM'
[patent_app_type] => utility
[patent_app_number] => 13/183617
[patent_app_country] => US
[patent_app_date] => 2011-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 8765
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0014/20120014947.pdf
[firstpage_image] =>[orig_patent_app_number] => 13183617
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/183617 | METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM | Jul 14, 2011 | Abandoned |
Array
(
[id] => 8027859
[patent_doc_number] => 08143011
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-03-27
[patent_title] => 'MAGE-C2 antigenic peptides and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/182037
[patent_app_country] => US
[patent_app_date] => 2011-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 24
[patent_no_of_words] => 19712
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/143/08143011.pdf
[firstpage_image] =>[orig_patent_app_number] => 13182037
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/182037 | MAGE-C2 antigenic peptides and uses thereof | Jul 12, 2011 | Issued |
Array
(
[id] => 7567939
[patent_doc_number] => 20110288002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-11-24
[patent_title] => 'NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM'
[patent_app_type] => utility
[patent_app_number] => 13/180232
[patent_app_country] => US
[patent_app_date] => 2011-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 39
[patent_no_of_words] => 10924
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0288/20110288002.pdf
[firstpage_image] =>[orig_patent_app_number] => 13180232
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/180232 | NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM | Jul 10, 2011 | Abandoned |
Array
(
[id] => 7710291
[patent_doc_number] => 20120003251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-05
[patent_title] => 'ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES'
[patent_app_type] => utility
[patent_app_number] => 13/173692
[patent_app_country] => US
[patent_app_date] => 2011-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 27396
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13173692
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/173692 | Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes | Jun 29, 2011 | Issued |
Array
(
[id] => 7587527
[patent_doc_number] => 20110282037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-11-17
[patent_title] => 'ANTIBODY PREPARATION'
[patent_app_type] => utility
[patent_app_number] => 13/162755
[patent_app_country] => US
[patent_app_date] => 2011-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 7571
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0282/20110282037.pdf
[firstpage_image] =>[orig_patent_app_number] => 13162755
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/162755 | ANTIBODY PREPARATION | Jun 16, 2011 | Abandoned |
Array
(
[id] => 7555109
[patent_doc_number] => 08067009
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2011-11-29
[patent_title] => 'Metalloproteinase oligopeptides and their therapeutic use'
[patent_app_type] => utility
[patent_app_number] => 13/159941
[patent_app_country] => US
[patent_app_date] => 2011-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 5696
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/067/08067009.pdf
[firstpage_image] =>[orig_patent_app_number] => 13159941
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/159941 | Metalloproteinase oligopeptides and their therapeutic use | Jun 13, 2011 | Issued |
Array
(
[id] => 9523851
[patent_doc_number] => 08748114
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-06-10
[patent_title] => 'ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)'
[patent_app_type] => utility
[patent_app_number] => 13/155198
[patent_app_country] => US
[patent_app_date] => 2011-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 24656
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13155198
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/155198 | ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) | Jun 6, 2011 | Issued |
Array
(
[id] => 8209009
[patent_doc_number] => 20120128661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-24
[patent_title] => 'POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER'
[patent_app_type] => utility
[patent_app_number] => 13/152209
[patent_app_country] => US
[patent_app_date] => 2011-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 37252
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0128/20120128661.pdf
[firstpage_image] =>[orig_patent_app_number] => 13152209
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/152209 | POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER | Jun 1, 2011 | Abandoned |
Array
(
[id] => 7488427
[patent_doc_number] => 20110251376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-10-13
[patent_title] => 'Mammalian Tumor Susceptibility Genes and their Uses'
[patent_app_type] => utility
[patent_app_number] => 13/116911
[patent_app_country] => US
[patent_app_date] => 2011-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 13090
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0251/20110251376.pdf
[firstpage_image] =>[orig_patent_app_number] => 13116911
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/116911 | Mammalian tumor susceptibility genes and their uses | May 25, 2011 | Issued |
Array
(
[id] => 8909623
[patent_doc_number] => 08481688
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-07-09
[patent_title] => 'Anti-FGFR2 antibodies'
[patent_app_type] => utility
[patent_app_number] => 13/105521
[patent_app_country] => US
[patent_app_date] => 2011-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 15497
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13105521
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/105521 | Anti-FGFR2 antibodies | May 10, 2011 | Issued |
Array
(
[id] => 7509779
[patent_doc_number] => 20110256056
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-10-20
[patent_title] => 'Monoclonal Antibodies Against HER2 Antigens, and Uses Therefor'
[patent_app_type] => utility
[patent_app_number] => 13/087351
[patent_app_country] => US
[patent_app_date] => 2011-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 18835
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0256/20110256056.pdf
[firstpage_image] =>[orig_patent_app_number] => 13087351
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/087351 | Monoclonal antibodies against HER2 antigens, and uses therefor | Apr 13, 2011 | Issued |